Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia.
Gestational trophoblastic disease includes complete hydatidiform mole (CHM) or partial hydatidiform mole (PHM) and gestational trophoblastic neoplasia (GTN). Given the very high-curability rate of trophoblastic disease, the risk of further molar pregnancy after CHM or PHM as well as the risk of second primary tumors and fertility compromise after chemotherapy for GTN represent major concerns. The incidence of subsequent molar pregnancy ranges from 0.7 to 2.6% after one CHM or PHM, and is approximately 10% after two previous CHMs. Among patients who have received chemotherapy, there is an increased risk of myeloid leukemia which is mainly related to the cumulative dose of etoposide. Resumption of normal menses occurs in approximately 95% of women treated with chemotherapy, but menopause occurs 3 years earlier compared with those non-treated with chemotherapy. Term live birth rates higher than 70% without increased risk of congenital abnormalities have been reported in these women, and pregnancy outcomes are comparable to those of general population, except a slightly increased risk of stillbirth. Fertility-sparing treatment for placental site trophoblastic tumor is a therapeutic option reserved to highly selected, young women who do not present markedly enlarged uterus or diffuse multifocal disease within the uterus.
a Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.
Angiolo
A
Gadducci
a Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.
Nora
N
Lanfredini
a Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.
Stefania
S
Cosio
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000628:therapy; D006801:Humans; D006828:Hydatidiform Mole / Q000628:therapy*; D015994:Incidence; D007951:Leukemia, Myeloid / Q000453:epidemiology*; D008594:Menopause, Premature; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D016609:Neoplasms, Second Primary / Q000453:epidemiology*; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D018873:Pregnancy Rate; D050497:Stillbirth / Q000453:epidemiology*; D014594:Uterine Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D005047:Etoposide
Chemotherapy; complete hydatidiform mole; gestational trophoblastic neoplasia; partial hydatiform mole; pregnancy